SI2797921T1 - Kondenzirani tetra- ali pentaciklični dihidrodiazepinokarbazoloni kot inhibitorji PARP - Google Patents

Kondenzirani tetra- ali pentaciklični dihidrodiazepinokarbazoloni kot inhibitorji PARP Download PDF

Info

Publication number
SI2797921T1
SI2797921T1 SI201131351T SI201131351T SI2797921T1 SI 2797921 T1 SI2797921 T1 SI 2797921T1 SI 201131351 T SI201131351 T SI 201131351T SI 201131351 T SI201131351 T SI 201131351T SI 2797921 T1 SI2797921 T1 SI 2797921T1
Authority
SI
Slovenia
Prior art keywords
heteroaryl
alkyl
heterocyclyl
cycloalkyl
aryl
Prior art date
Application number
SI201131351T
Other languages
English (en)
Inventor
Changyou Zhou
Bo Ren
Hexiang Wang
Original Assignee
Beigene, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene, Ltd. filed Critical Beigene, Ltd.
Publication of SI2797921T1 publication Critical patent/SI2797921T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (12)

  1. EP 2797921 BI Kondenzirani tetra- ali pentaciklični dihidrodiazepinokarbazoloni kot ihibitorji PARP Patentni zahtevki
    1. Spojina, izbrana iz spojine s formulo (I):
    ali njenega stereoizomera ali njene farmacevtsko sprejemljive soli, kjer: Rn je izbran izmed vodika, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; X je izbran iz skupine, ki jo sestavljajo C, N, O in S; m in n, ki sta lahko enaka ali različna, sta lahko vsak celo število 0, 1, 2 ali 3; t je celo število 0, 1,2 ali 3; R1 je vsakokrat, ko se pojavi, neodvisno izbran izmed halogena, CN, N02, OR9, NR9R10, NR9COR10, NR9S02R10, CONR9R10, COOR9, S02R9, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno 17 po izbiri substituiran z vsaj enim substituentom R ; R2 je izbran izmed vodika, COR9, CONR9R10, CO2R9, SO2R9, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; R3, R4, R5, R6, R7 in R8 so lahko enaki ali različni, vsak od njih pa je neodvisno izbran izmed vodika, halogena, -NR9R10, -OR9, okso, -COR9, -C02R9, -CONR9R10, -NR9CONR10Ru, -NR9C02R10, -NR9S02R10, -S02R9, alkila, alkenila, cikloalkila, arila, heterociklila, alkinila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, arila, heterociklila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12, ali (R3 in R4) in/ali (R4 in R5) in/ali (R5 in R6) in/ali (R6 in R7) in/ali (R7 in R8) skupaj z atomom/atomi, na katerega/katere so vezani, tvorijo 3-8-členski nasičen, delno ali popolnoma nenasičen obroč, ki ima 0, 1 ali 2 heteroatoma, neodvisno izbrana izmed -NR13-, -O-, -S-, -SO- ali -S02-, in je ta obroč po izbiri substituiran z vsaj enim substituentom R12, pod pogojem, da kadar je X O, sta R5 in R6 odsotna, kadar je X N, je R6 odsoten, kadar je X S, sta R5 in R6 odsotna ali je vsaj eden od R5 in R6 okso, kadar je eden od R3 in R4 okso, je drugi odsoten, kadar je eden od R7 in R8 okso, je drugi odsoten, in kadar je X C in je eden od R5 in R6 okso, je drugi odsoten; R9, R10 in R11 so lahko enaki ali različni, vsak od njih pa je izbran izmed vodika, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R ; R12 je izbran izmed CN, halogena, haloalkila, NO2, -NR'R", -OR', okso, -COR', -C02R', -CONR'R", -NR'CONR"R'", -NR'C02R", -NR'S02R", -SO2R', alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer so R', R" in R'" neodvisno izbrani izmed vodika, haloalkila, alkila, arilalkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, ali (R' in R") in/ali (R” in R'") skupaj z atomom/atomi, na katerega/katere so vezani, tvorijo 3-8-členski nasičen, delno ali popolnoma nenasičen obroč, ki ima 0, 1 ali 2 dodatna heteroatoma, neodvisno izbrana izmed -NR -, -O-, -S-, -SO- in S02-; R13 je izbran izmed vodika, alkila, cikloalkila, arila, heteroarila in heterociklila.
  2. 2. Spojina po zahtevku 1, ki je izbrana iz spojine s formulo (II):
    (II) ali njenega stereoizomera ali njene farmacevtsko sprejemljive soli, kjer: Rn je izbran izmed vodika, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; m in n, ki sta lahko enaka ali različna, sta vsak celo število 0, 1,2 ali 3; t je celo število 0, 1,2 ali 3; R1 je vsakokrat, ko se pojavi, neodvisno izbran izmed halogena, CN, N02, OR9, NR9R10, NR9COR10, NR9S02R10, CONR9R10, COOR9, SOzR9, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; R2 je izbran izmed vodika, COR9, CONR9R10, CO2R9, SO2R9, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R ; R3, R4, R5, R6, R7 in R8 so lahko enaki ali različni, vsak od njih pa je neodvisno izbran izmed vodika, halogena, -NR9R10, -OR9, okso, -COR9, -CO2R9, -CONR9R10, -NR9CONR,0Rn, -NR9C02R10, -NR9S02R10, -S02R9, alkila, alkenila, cikloalkila, arila, heterociklila, alkinila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, arila, heterociklila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12, ali (R3 in R4) in/ali (R4 in R5) in/ali (R5 in R6) in/ali (R6 in R7) in/ali (R7 in R8) skupaj z atomom/atomi, na katerega/katere so vezani, tvorijo 3-8-členski nasičen, delno ali popolnoma nenasičen obroč, ki ima 0, 1 ali 2 heteroatoma, neodvisno izbrana izmed -NR13-, -O-, -S-, -SO- in -SO2-, in je ta obroč po izbiri substituiran z vsaj enim substituentom R12, pod pogojem, da kadar je eden od R3 in R4 okso, je drugi odsoten, kadar je eden od R7 in R8 okso, je drugi odsoten, in kadar je eden od R5 in R6 okso, je drugi odsoten; R9, R10 in R11 so lahko enaki ali različni, vsak od njih pa je izbran izmed vodika, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; R12 je izbran izmed CN, halogena, haloalkila, NO2, -NR'R", -OR', okso, -COR', -C02R', -CONR'R", -NR'CONR"R'", -NR'C02R”, -NR'S02R", -S02R', alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer so R', R" in R"' neodvisno izbrani izmed vodika, haloalkila, alkila, arilalkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, ali (R' in R") in/ali (R" in R"') skupaj z atomom/atomi, na katerega/katere so vezani, tvorijo 3-8-členski nasičen, delno ali popolnoma nenasičen obroč, ki ima 0, 1 ali 2 dodatna heteroatoma, neodvisno izbrana izmed -NR13-, -O-, -S-, -SO- ali -S02-, R13 je izbran izmed vodika, alkila, cikloalkila, arila, heteroarila in heterociklila.
  3. 3. Spojina po zahtevku 1, kije izbrana iz spojine s formulo (III):
    ali njenega stereoizomera ali njene farmacevtsko sprejemljive soli, kjer: Rn je izbran izmed vodika, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; m in n, ki sta lahko enaka ali različna, sta vsak celo število 0, 1,2 ali 3; t je celo število 0, 1,2 ali 3; R1 je vsakokrat, ko se pojavi, neodvisno izbran izmed halogena, CN, N02, OR9, NR9R10, NR9COR10, NR9S02R1c, CONR9R10, COOR9, S02R9, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R ; R2 je izbran izmed vodika, COR9, CONR9R10, C02R9, S02R9, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; R3, R4, R5, R7 in R8 so lahko enaki ali različni, vsak od njih pa je neodvisno izbran izmed vodika, halogena, -NR9R10, -OR9, okso, -COR9, -CO2R9, -CONR9R10, -NR9CONR10Ru, -NR9C02Rl°, -NR9S02R10, -S02R9, alkila, alkenila, cikloalkila, arila, heterociklila, alkinila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, arila, heterociklila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12, ali (R3 in R4) in/ali (R4 in R5) in/ali (R5 in R7) in/ali (R7 in R8) skupaj z atomom/atomi, na katerega/katere so vezani, tvorijo 3-8-členski nasičen, delno ali popolnoma nenasičen obroč, ki ima 0, 1 ali 2 heteroatoma, neodvisno izbrana izmed -NR -, -O-, -S-, -SO- in -S02-, in je ta obroč po izbiri substituiran z vsaj enim substituentom R12, pod pogojem, da kadar je eden od R3 in R4 okso, je drugi odsoten, in kadar je eden od R7 in R8 okso, je drugi odsoten; R9, R10 in R11 so lahko enaki ali različni, vsak od njih pa je izbran izmed vodika, alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer je vsak od alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila neodvisno po izbiri substituiran z vsaj enim substituentom R12; R12 je izbran izmed CN, halogena, haloalkila, N02, -NR'R", -OR', okso, -COR', -C02R', -CONR'R", -NR'CONR''R'", -NR’C02R", -NR'S02R", -S02R', alkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, kjer so R', R" in R'" neodvisno izbrani izmed vodika, haloalkila, alkila, arilalkila, alkenila, alkinila, cikloalkila, heterociklila, arila in heteroarila, ali (R' in R") in/ali (R" in R'") skupaj z atomom/atomi, na katerega/katere so vezani, tvorijo 3-8-členski nasičen, delno ali popolnoma nenasičen obroč, ki ima 0, 1 ali 2 dodatna heteroatoma, neodvisno izbrana izmed -NR13-, -0-, -S-, -SO- ali -S02-; in R13 je izbran izmed vodika, alkila, cikloalkila, arila, heteroarila in heterociklila.
  4. 4. Spojina po zahtevku 3, kjer je tako m kot tudi n celo število 1.
  5. 5. Spojina po zahtevku 3, kjer je t enak 1 in je R1 halogen ali alkil.
  6. 6. Spojina po zahtevku 3, kjer je R2 vodik.
  7. 7. Spojina po zahtevku 3, kjer R4 in R5 skupaj z atomom/atomi, na katerega/katere sta vezana, tvorita 5-členski nasičen obroč, ki ima en heteroatom dušik.
  8. 8. Spojina po katerem koli prejšnjem zahtevku, kije izbrana izmed naslednjih spojin:
    ali njihovega stereoizomera ali njihove farmacevtsko sprejemljive soli.
  9. 9. Spojina po katerem koli prejšnjem zahtevku, kije:
    ali njen stereoizomer ali njena farmacevtsko sprejemljiva sol.
  10. 10. Farmacevtski sestavek, ki obsega vsaj en farmacevtsko sprejemljiv nosilec in kot aktivno sestavino terapevtsko učinkovito količino spojine po katerem koli od zahtevkov 1-9 ali njenega stereoizomera ali njene farmacevtsko sprejemljive soli.
  11. 11. Spojina po katerem koli od zahtevkov 1-9 ali njen stereoizomer ali njena farmacevtsko sprejemljiva sol za uporabo pri zdravljenju raka, ki se odziva na inhibicijo poli(ADP-riboza) polimeraze.
  12. 12. Spojina po katerem koli od zahtevkov 1-9 ali njen stereoizomer ali njena farmacevtsko sprejemljiva sol za uporabo pri zdravljenju vsaj ene bolezni, ki se odziva na inhibicijo poli(ADP-riboza)polimeraze.
SI201131351T 2011-12-31 2011-12-31 Kondenzirani tetra- ali pentaciklični dihidrodiazepinokarbazoloni kot inhibitorji PARP SI2797921T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11878508.8A EP2797921B1 (en) 2011-12-31 2011-12-31 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
PCT/CN2011/085148 WO2013097225A1 (en) 2011-12-31 2011-12-31 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Publications (1)

Publication Number Publication Date
SI2797921T1 true SI2797921T1 (sl) 2018-01-31

Family

ID=48696280

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131351T SI2797921T1 (sl) 2011-12-31 2011-12-31 Kondenzirani tetra- ali pentaciklični dihidrodiazepinokarbazoloni kot inhibitorji PARP

Country Status (29)

Country Link
US (4) US9260440B2 (sl)
EP (2) EP2797921B1 (sl)
JP (1) JP6034877B2 (sl)
KR (1) KR101716012B1 (sl)
CN (2) CN106220635B (sl)
AU (1) AU2011384858B2 (sl)
BR (1) BR112014012628B8 (sl)
CA (1) CA2856309C (sl)
CY (1) CY1119804T1 (sl)
DK (1) DK2797921T3 (sl)
EA (1) EA027533B1 (sl)
ES (1) ES2645814T3 (sl)
HK (1) HK1192233A1 (sl)
HR (1) HRP20171883T1 (sl)
HU (1) HUE035153T2 (sl)
IL (1) IL233365A (sl)
IN (1) IN2014DN06169A (sl)
LT (1) LT2797921T (sl)
ME (1) ME02855B (sl)
MX (1) MX353578B (sl)
NO (1) NO2797921T3 (sl)
NZ (1) NZ624063A (sl)
PL (1) PL2797921T3 (sl)
PT (1) PT2797921T (sl)
RS (1) RS56616B1 (sl)
SG (1) SG11201401726VA (sl)
SI (1) SI2797921T1 (sl)
WO (1) WO2013097225A1 (sl)
ZA (1) ZA201405560B (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097225A1 (en) 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
KR102104144B1 (ko) 2012-03-07 2020-04-23 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CA2994895A1 (en) * 2015-08-25 2017-03-02 Beigene, Ltd. Process for preparing parp inhibitor, crystalline forms, and uses thereof
CN113717170A (zh) * 2016-04-01 2021-11-30 里科瑞尔姆Ip控股有限责任公司 ***受体调节剂
WO2018059437A1 (en) 2016-09-27 2018-04-05 Beigene, Ltd. Treatment cancers using combination comprising parp inhibitors
TW201840564A (zh) * 2017-02-28 2018-11-16 英屬開曼群島商百濟神州有限公司 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途
CN106883232B (zh) * 2017-03-31 2019-01-22 苏州康润医药有限公司 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用
CN110891576A (zh) * 2017-07-17 2020-03-17 百济神州有限公司 使用包含parp抑制剂、替莫唑胺和/或放射疗法的组合治疗癌症
WO2019228499A1 (en) * 2018-06-01 2019-12-05 Beigene, Ltd. Maintenance therapy of a parp inhibitor in treating gastric cancer
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法
CN111171002B (zh) * 2019-05-16 2021-04-06 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的制备方法
BR112021018847A2 (pt) 2019-05-31 2021-11-30 Beigene Ltd Composições de pélete, método para preparar uma composição de pélete, formulação oral de inibidor de parp, método para tratar uma doença associada à parp
CA3148221A1 (en) 2019-08-06 2021-02-11 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445326B (sv) 1983-04-05 1986-06-16 Malmstroem Anders E H Sett och anordning for forhindrande av veggturbulens
US6799298B2 (en) 1998-03-11 2004-09-28 Overture Services, Inc. Technique for locating an item of interest within a stored representation of data
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
CA2430363C (en) 2000-12-01 2010-04-13 Guilford Pharmaceuticals Inc. Compounds and their uses
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
US6906096B2 (en) 2002-06-28 2005-06-14 Irm Llc 4,7-Disubstituted indoles and methods of making
DE602004015724D1 (de) 2003-01-09 2008-09-25 Pfizer Diazepinoindolderivate als kinaseinhibitoren
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
CA2648369A1 (en) 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
BRPI0709731A2 (pt) 2006-04-04 2011-07-26 Pfizer Prod Inc terapia de combinaÇço de (2r,z)-2-amino-2-cicloexil-n-(5-(1-metil-1h-pirazol-4-il)-1- oxo-2,6-diidro-1h-[1,2]diazepino[4,5,6-cd]indol-8-il)acet amida
BRPI0820236A2 (pt) 2007-11-15 2015-06-16 Angeletti P Ist Richerche Bio Derivados de piridazinona como inibidores parp
AU2009279944B2 (en) * 2008-08-06 2014-09-11 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2013097225A1 (en) 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
CA3080200A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
CA2994895A1 (en) 2015-08-25 2017-03-02 Beigene, Ltd. Process for preparing parp inhibitor, crystalline forms, and uses thereof
WO2018059437A1 (en) 2016-09-27 2018-04-05 Beigene, Ltd. Treatment cancers using combination comprising parp inhibitors
TW201840564A (zh) 2017-02-28 2018-11-16 英屬開曼群島商百濟神州有限公司 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途
CN110891576A (zh) 2017-07-17 2020-03-17 百济神州有限公司 使用包含parp抑制剂、替莫唑胺和/或放射疗法的组合治疗癌症

Also Published As

Publication number Publication date
NO2797921T3 (sl) 2018-02-03
US9260440B2 (en) 2016-02-16
PT2797921T (pt) 2017-11-14
CA2856309C (en) 2016-06-07
US20160159811A1 (en) 2016-06-09
ES2645814T3 (es) 2017-12-07
HRP20171883T1 (hr) 2018-01-12
CA2856309A1 (en) 2013-07-04
US9617273B2 (en) 2017-04-11
BR112014012628B1 (pt) 2021-02-09
JP6034877B2 (ja) 2016-11-30
IL233365A (en) 2016-08-31
PL2797921T3 (pl) 2018-02-28
EP3315500B1 (en) 2020-03-18
US20190016731A1 (en) 2019-01-17
AU2011384858B2 (en) 2016-05-05
JP2015503526A (ja) 2015-02-02
ZA201405560B (en) 2017-02-22
US10112952B2 (en) 2018-10-30
ME02855B (me) 2018-04-20
NZ624063A (en) 2016-09-30
RS56616B1 (sr) 2018-02-28
HK1192233A1 (zh) 2014-08-15
CY1119804T1 (el) 2018-06-27
BR112014012628A2 (pt) 2017-06-13
SG11201401726VA (en) 2014-10-30
KR101716012B1 (ko) 2017-03-13
BR112014012628B8 (pt) 2023-01-17
MX353578B (es) 2018-01-19
WO2013097225A1 (en) 2013-07-04
KR20140107353A (ko) 2014-09-04
EP2797921B1 (en) 2017-09-06
CN106220635B (zh) 2019-03-08
CN103703004B (zh) 2016-06-29
EP3315500A1 (en) 2018-05-02
HUE035153T2 (en) 2018-05-02
AU2011384858A1 (en) 2014-05-29
EP2797921A1 (en) 2014-11-05
MX2014007840A (es) 2014-08-21
LT2797921T (lt) 2017-11-27
US10501467B2 (en) 2019-12-10
CN106220635A (zh) 2016-12-14
EA201491303A1 (ru) 2014-10-30
US20170305921A1 (en) 2017-10-26
IN2014DN06169A (sl) 2015-08-21
EP2797921A4 (en) 2015-10-21
EA027533B1 (ru) 2017-08-31
DK2797921T3 (en) 2017-10-02
CN103703004A (zh) 2014-04-02
US20150175617A1 (en) 2015-06-25
IL233365A0 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
SI2797921T1 (sl) Kondenzirani tetra- ali pentaciklični dihidrodiazepinokarbazoloni kot inhibitorji PARP
HRP20200352T1 (hr) Novi kondenzirani pirimidinski spoj ili njegova sol
JP2013528600A5 (sl)
JP2014513138A5 (sl)
JP2016506962A5 (sl)
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
AR066078A1 (es) Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos.
NZ710745A (en) Pyrrolobenzodiazepines and conjugates thereof
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
JP2017528524A5 (sl)
RU2018112252A (ru) Конденсированное пиримидиновое соединение или его соль
SI2809657T1 (sl) Nova terapevtska sredstva
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
JP2012507566A5 (sl)
SI20691B (sl) Triciklični inhibitorji poli(ADP-riboza) polimeraz
MA35833B1 (fr) Dérivés de bétuline
GB201201744D0 (en) Novel compounds
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
JP2016513696A5 (sl)
SI2483271T1 (sl) Derivati pirazolin diona kot inhibitorji nadph-oksidaze
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
SI2953948T1 (sl) Fluorinirani integrin antagonisti
JP2019532033A5 (sl)
RU2015147447A (ru) Производные доластатина 10 и ауристатинов